Testing a new antibody treatment for methamphetamine use disorder
Official title: OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder
Funded at Intervexion Therapeutics, LLC · NIH-10686245 · Data updated 2026-11-12
This study is testing a new treatment called IXT-m200 to see if it can help people with methamphetamine use disorder stay off meth and reduce their chances of relapsing, and it's open to about 120 participants who will receive the treatment over six months.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Intervexion Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Little Rock, United States) |
| Project start | September 30, 2021 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $4,609,902 |
| NIH project number | 5U01DA055481-03 |
| Project ID | NIH-10686245 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with methamphetamine use disorder who are seeking treatment.
✕Less likely to help
Patients who do not have a diagnosis of methamphetamine use disorder or those who are not seeking treatment may not benefit from this research.
What this research studies
This research investigates the efficacy of IXT-m200, an anti-methamphetamine monoclonal antibody, in treating individuals with methamphetamine use disorder (MUD). Participants will receive multiple doses of the antibody over six months, with the aim of reducing relapse rates to methamphetamine use. The study will involve approximately 120 participants, who will be monitored for safety and effectiveness as the treatment alters how methamphetamine is processed in the body. The research seeks to provide a new therapeutic option for a condition that currently lacks approved medications.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option for individuals struggling with methamphetamine use disorder.
How similar studies have gone: Previous studies have shown that single doses of IXT-m200 are safe, but this is the first multiple-dose study specifically targeting methamphetamine use disorder.
Where this research is happening
-
Intervexion Therapeutics, LLC
Little Rock, United States Active
Researchers
- Principal investigator: Stevens, Misty Ward — Intervexion Therapeutics, LLC
- Study coordinator: Stevens, Misty Ward
Related research
Other NIH-funded projects on the same topics.
-
Developing a long-lasting treatment for methamphetamine addiction
This study is working on a new treatment for people with methamphetamine use disorder by developing a special antibody that can help lessen the effects of the drug, making it easier for them to stick to their recovery plan.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.